Navigation Links
Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
Date:9/24/2007

PROPEL Enrollment Ahead of Schedule with Completion Expected Q2 2008

WESTMINSTER, Colo., Sept. 24 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the completion of pre-planned interim analyses of patient response and safety data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Results of the interim analysis of patient response data exceeded the pre-specified threshold for continuation of the trial, which required a minimum of four responses (complete or partial) out of the first 35 evaluable patients, as determined by independent oncology review. In addition, an independent Data Monitoring Committee (DMC) completed an interim analysis of the safety data from the first 35 evaluable patients and recommended that the trial continue per the protocol. No major safety concerns were identified by the DMC.

In accordance with the trial protocol, the DMC will conduct another interim analysis of safety data from the first 65 evaluable patients. The Company expects to report the outcome of the 65-patient safety analysis by the end of 2007. Additionally, the Company now expects to complete enrollment in the PROPEL trial in the second quarter of 2008.

"The outcomes of these interim analyses represent continued progress toward the completion of the PROPEL trial and an important milestone in the development of a potential new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma," said Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. "We are pleased with the progress of the PROPEL trial and look forward to completing enrollment in the second quarter
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Cynosure, Inc. (NASDAQ: ... for non-invasive and minimally invasive applications, today announced that the ... Officer and Chief Financial Officer Timothy W. Baker ... 53, will continue to serve as CFO and will take ... remains Chairman and Chief Executive Officer. "Tim ...
(Date:7/30/2014)... N.J. and SAN DIEGO , ... (NASDAQ: ARNA ) announced today that an article ... trials of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, ... Outcomes," was recently published in the online issue of ... Society. The objective of these analyses was to identify whether ...
(Date:7/30/2014)... /PRNewswire-iReach/ -- This is a professional and in-depth ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) industry. The ... sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) including ... then explores global and China,s top manufacturers of ... listing their product specification, capacity, production value, cost, ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... , ST. LOUIS, Jan. 11 KV Pharmaceutical Company ... the existing asset purchase agreement with Hologic, Inc. to secure the ... and conditions set forth in the amendment. Upon approval by the ... first and only FDA-approved treatment for the prevention of preterm birth ...
... N.J., Jan. 11 Survival of the fittest? In ... only what you know today, but what you need to ... has the right insight and accurate forecasting skills will excel. ... growing) market in the world, its sheer size also presents ...
Cached Medicine Technology:KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM) 2KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM) 3KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM) 4KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM) 5KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM) 6KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM) 7Elite Pharma Insiders to Reveal Key Survival Strategies for Pharmaceutical Industry in 2010 2
(Date:7/30/2014)... Bay Aquarium Research Institute (MBARI) have observed a deep-sea ... yearslonger than any other known animal. Throughout this time, ... from predators. This amazing feat represents an evolutionary balancing ... having plenty of time to develop within their eggs, ... little or no food. , Every few months for ...
(Date:7/30/2014)... Frozen shoulder (Adhesive capsulitis) affects 10-20 percent ... this nasty condition which occurs most frequently in people between ... to two and half years if not treated. , Adhesive ... good reason: it can render your shoulder so stiff, it's ... you aren't in too much pain to get dressed in ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- For patients ... is enough to trigger airway inflammation for at least ... just what you smell, but also what you think ... Monell Chemical Senses Center in Philadelphia, said in a ... about scents and fragrances. When we expect that an ...
(Date:7/30/2014)... vast majority of kids with autism have abnormal sensory ... children who have trouble processing sensory stimuli, researchers report. ... overly sensitive to sound, sight and touch. They can ... of concentration. Complicating matters, some kids with SPD ... tolerating loud noises, like a vacuum. Others can,t hold ...
(Date:7/30/2014)... adults who were breastfed for three months or ... of chronic inflammation associated with cardiovascular and metabolic ... at Washington University in St. Louis. , "This ... implications for children,s health decades later," said Molly ... School and a co-author of the study with ...
Breaking Medicine News(10 mins):Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2
... to stop overdoses in heroin addicts. Hence many needle ... The news follows the deaths of at least 400 ... ,Prevention Point Philadelphia, a nonprofit organization responsible for ... distribution of naloxone prescriptions through a physician. "If people ...
... Gainesville, mice based experiments were found to be successful in ... , This new technique was found to be successful ... The findings, published July 27 in the online edition of ... could begin as soon as early next year for patients ...
... researchers at the University of Geneva it was found that ... smokers. // ,NRT is mainly to wean smokers off ... their normal health. But according to these researchers they have ... 7.2% among smokers for a period of four years. ...
... effectiveness of a bird flu vaccine against the deadly H5N1 ... and unvaccinated monkeys, by researchers at two universities.// ... Hokkaido University, the results are expected to be known within ... could shed light on numerous aspects of the strain's infection ...
... drug is beginning to light up the lives of thousands ... of the kidney and the gut.// Initial examinations of the ... breast, lung and pancreatic cancers. ,This drug ... an important enzyme that causes the cells to proliferate rapidly, ...
... U.S. Department of Agriculture have indicated the enhanced nutritive ... Watermelon. // ,According to scientists, watermelons are ... severed from the parent plant, which slows down once ... kept at 70 degrees, contained almost 40% of lycopene ...
Cached Medicine News:Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 3Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 4
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: